Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Development of nano-carriers for Leishmania vaccine delivery.

Askarizadeh A, Badiee A, Khamesipour A.

Expert Opin Drug Deliv. 2020 Jan 14:1-21. doi: 10.1080/17425247.2020.1713746. [Epub ahead of print]

PMID:
31914821
2.

Conducting International Diploma Course on Leishmaniasis and Its Control in the Islamic Republic of Iran.

Yaghoobi-Ershadi MR, Akhavan AA, Shirzadi MR, Rassi Y, Khamesipour A, Hanafi-Bojd AA, Vatandoost H.

J Arthropod Borne Dis. 2019 Sep 30;13(3):234-242. eCollection 2019 Sep. Review.

3.

Old world cutaneous leishmaniasis in Iran: clinical variants and treatments.

Firooz A, Mortazavi H, Khamesipour A, Ghiasi M, Abedini R, Balighi K, Esmaili N, Nassiri-Kashani M, Eskandari SE, Mohebali M, Mir Amin Mohammadi A, Dowlati Y.

J Dermatolog Treat. 2020 Jan 8:1-11. doi: 10.1080/09546634.2019.1704214. [Epub ahead of print]

PMID:
31869258
4.

Comparative analysis between four model nanoformulations of amphotericin B-chitosan, amphotericin B-dendrimer, betulinic acid-chitosan and betulinic acid-dendrimer for treatment of Leishmania major: real-time PCR assay plus.

Zadeh Mehrizi T, Khamesipour A, Shafiee Ardestani M, Ebrahimi Shahmabadi H, Haji Molla Hoseini M, Mosaffa N, Ramezani A.

Int J Nanomedicine. 2019 Sep 24;14:7593-7607. doi: 10.2147/IJN.S220410. eCollection 2019.

5.

Salvage therapy with Sodium chlorosum (formerly DAC N-055) for cases of refractory lupoid cutaneous leishmaniasis: results from a compassionate use study with 0.09% Sodium chlorosum in amphiphilic basic cream.

Molkara S, Poursoltani E, Stahl KW, Maleki M, Khamesipour A, Bogdan C, Salehi M, Goyonlo VM.

BMC Infect Dis. 2019 Nov 28;19(1):1005. doi: 10.1186/s12879-019-4518-x.

6.

Development of a topical liposomal formulation of Amphotericin B for the treatment of cutaneous leishmaniasis.

Jaafari MR, Hatamipour M, Alavizadeh SH, Abbasi A, Saberi Z, Rafati S, Taslimi Y, Mohammadi AM, Khamesipour A.

Int J Parasitol Drugs Drug Resist. 2019 Dec;11:156-165. doi: 10.1016/j.ijpddr.2019.09.004. Epub 2019 Sep 23.

7.

Safety Evaluation of Topical Application of Nano-Liposomal Form of Amphotericin B (SinaAmpholeish) on Healthy Volunteers: Phase I Clinical Trial.

Eskandari SE, Firooz A, Nassiri-Kashani M, Jaafari MR, Javadi A, Miramin Mohammadi A, Khamesipour A.

Iran J Parasitol. 2019 Apr-Jun;14(2):197-203.

8.

An overview of leishmanization experience: A successful control measure and a tool to evaluate candidate vaccines.

Mohebali M, Nadim A, Khamesipour A.

Acta Trop. 2019 Dec;200:105173. doi: 10.1016/j.actatropica.2019.105173. Epub 2019 Sep 13. Review.

PMID:
31525323
9.

Associated-risk determinants for anthroponotic cutaneous leishmaniasis treated with meglumine antimoniate: A cohort study in Iran.

Aflatoonian MR, Sharifi I, Aflatoonian B, Bamorovat M, Heshmatkhah A, Babaei Z, Ghasemi Nejad Almani P, Mohammadi MA, Salarkia E, Aghaei Afshar A, Sharifi H, Sharifi F, Khosravi A, Khatami M, Arefinia N, Fekri A, Farajzadeh S, Khamesipour A, Mohebali M, Gouya MM, Shirzadi MR, Varma RS.

PLoS Negl Trop Dis. 2019 Jun 12;13(6):e0007423. doi: 10.1371/journal.pntd.0007423. eCollection 2019 Jun.

10.

Niosomal formulation of amphotericin B alone and in combination with glucantime: In vitro and in vivo leishmanicidal effects.

Mostafavi M, Sharifi I, Farajzadeh S, Khazaeli P, Sharifi H, Pourseyedi E, Kakooei S, Bamorovat M, Keyhani A, Parizi MH, Khosravi A, Khamesipour A.

Biomed Pharmacother. 2019 Aug;116:108942. doi: 10.1016/j.biopha.2019.108942. Epub 2019 May 30.

11.

Generation of a CRISPR/Cas9-Based Vector Specific for Gene Manipulation in Leishmania major.

Salehi Sangani G, Jajarmi V, Khamesipour A, Mahmoudi M, Fata A, Mohebali M.

Iran J Parasitol. 2019 Jan-Mar;14(1):78-88.

12.
13.

Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice.

Kavian Z, Alavizadeh SH, Golmohamadzadeh S, Badiee A, Khamesipour A, Jaafari MR.

Acta Trop. 2019 Aug;196:142-149. doi: 10.1016/j.actatropica.2019.05.018. Epub 2019 May 16.

PMID:
31103698
14.

Leishmania major p27 gene knockout as a novel live attenuated vaccine candidate: Protective immunity and efficacy evaluation against cutaneous and visceral leishmaniasis in BALB/c mice.

Elikaee S, Mohebali M, Rezaei S, Eslami H, Khamesipour A, Keshavarz H, Eshraghian MR.

Vaccine. 2019 May 27;37(24):3221-3228. doi: 10.1016/j.vaccine.2019.04.068. Epub 2019 Apr 29.

PMID:
31047672
15.

A Survey on the Adjuvant Role of Naloxone Alone or Combined with Alum in Vaccination Against Fasciolosis in BALB/c Mice.

Azizi H, Mirzaeei H, Bagheri A, Bazi A, Khamesipour A, Yaghoobi H, Mirzapour A, Khatami M, Elikaee S.

Acta Parasitol. 2019 Jun;64(2):236-245. doi: 10.2478/s11686-019-00030-2. Epub 2019 Feb 20.

PMID:
30788648
16.

Hepatoprotective and antioxidant effects of Hedera helix extract on acetaminophen induced oxidative stress and hepatotoxicity in mice.

Moshaie-Nezhad P, Faed Maleki F, Hosseini SM, Yahyapour M, Iman M, Khamesipour A.

Biotech Histochem. 2019 Jul;94(5):313-319. doi: 10.1080/10520295.2019.1566569. Epub 2019 Feb 19.

PMID:
30777790
17.

Speeding up the discovery of combinations of differentially expressed genes for disease prediction and classification.

Khamesipour A, Kagaris D.

Comput Methods Programs Biomed. 2019 Mar;170:69-80. doi: 10.1016/j.cmpb.2019.01.004. Epub 2019 Jan 12.

PMID:
30712605
18.

Safety Evaluation of Nano-Liposomal Formulation of Amphotericin B (Sina Ampholeish) in Animal Model as a Candidate for Treatment of Cutaneous Leishmaniasis.

Eskandari SE, Firooz A, Nassiri-Kashani M, Jaafari MR, Javadi A, Miramin-Mohammadi A, Valian-Keshavarz H, Khamesipour A.

J Arthropod Borne Dis. 2018 Sep 30;12(3):269-275. eCollection 2018 Sep.

19.

Novel nano-sized chitosan amphotericin B formulation with considerable improvement against Leishmania major.

Mehrizi TZ, Ardestani MS, Molla Hoseini MH, Khamesipour A, Mosaffa N, Ramezani A.

Nanomedicine (Lond). 2018 Dec;13(24):3129-3147. doi: 10.2217/nnm-2018-0063. Epub 2018 Nov 22.

PMID:
30463469
20.

Gene expression of RNAP II, JBP1 and JBP2 in Leishmania major exposed to antimonials, amphotericin B and paromomycin

Ajamein V, Eslami G, Ahmadian S, Khamesipour A, Elloumi M.

Ann Parasitol. 2018;64(3):181-187. doi: 10.17420/ap6403.149.

21.

The Potential Role of Humans in the Transmission Cycle of Leishmania major (Kinetoplastida: Trypanosomatidae), the Causative Agent of the Old World Zoonotic Cutaneous Leishmaniasis.

Fatemi M, Yaghoobi-Ershadi MR, Mohebali M, Saeidi Z, Veysi A, Gholampour F, Akhondi B, Karimi A, Arandian MH, Amin Mohammadi AM, Rassi Y, Zahraei-Ramazani A, Khamesipour A, Akhavan AA.

J Med Entomol. 2018 Oct 25;55(6):1588-1593. doi: 10.1093/jme/tjy110.

PMID:
30124876
22.

Novel Nanosized Chitosan-Betulinic Acid Against Resistant Leishmania Major and First Clinical Observation of such parasite in Kidney.

Zadeh Mehrizi T, Shafiee Ardestani M, Haji Molla Hoseini M, Khamesipour A, Mosaffa N, Ramezani A.

Sci Rep. 2018 Aug 6;8(1):11759. doi: 10.1038/s41598-018-30103-7.

23.

Reduction toxicity of Amphotericin B through loading into a novel nanoformulation of anionic linear globular dendrimer for improve treatment of leishmania major.

Mehrizi TZ, Ardestani MS, Khamesipour A, Hoseini MHM, Mosaffa N, Anissian A, Ramezani A.

J Mater Sci Mater Med. 2018 Jul 28;29(8):125. doi: 10.1007/s10856-018-6122-9.

PMID:
30056571
24.

Development of a new live attenuated Leishmania major p27 gene knockout: Safety and immunogenicity evaluation in BALB/c mice.

Elikaee S, Mohebali M, Rezaei S, Eslami H, Khamesipour A, Keshavarz H, Eshraghian MR.

Cell Immunol. 2018 Oct;332:24-31. doi: 10.1016/j.cellimm.2018.07.002. Epub 2018 Jul 17.

PMID:
30053997
25.

AUCTSP: an improved biomarker gene pair class predictor.

Kagaris D, Khamesipour A, Yiannoutsos CT.

BMC Bioinformatics. 2018 Jun 26;19(1):244. doi: 10.1186/s12859-018-2231-1.

26.

The role of MPL and imiquimod adjuvants in enhancement of immune response and protection in BALB/c mice immunized with soluble Leishmania antigen (SLA) encapsulated in nanoliposome.

Emami T, Rezayat SM, Khamesipour A, Madani R, Habibi G, Hojatizade M, Jaafari MR.

Artif Cells Nanomed Biotechnol. 2018;46(sup2):324-333. doi: 10.1080/21691401.2018.1457042. Epub 2018 Apr 1.

PMID:
29607698
27.

Evaluation of Association Between the Serum Levels of MMP-9 and MMP-9/TIMPs With Soluble Forms of Selectins and Itching Induced by Sulfur Mustard.

Askari N, Ghazanfari T, Naghizadeh MM, Moin A, Khamesipour A, Pourfarzam S, Hassan ZM.

Iran J Pathol. 2017 Summer;12(3):257-264. Epub 2017 Jan 27.

28.

Rearing and Biology of Phlebotomus sergenti, the Main Vector of Anthroponotic Cutaneous Leishmaniasis in Iran.

Veysi A, Yaghoobi-Ershadi MR, Rassi Y, Hosseini-Vasoukolaei N, Jeddi-Tehrani M, Rezaee-Node A, Gholampour F, Saeidi Z, Fatemi M, Arandian MH, Khamesipour A, Akhavan AA.

J Arthropod Borne Dis. 2017 Dec 30;11(4):504-514. eCollection 2017 Dec.

29.

Harmonized clinical trial methodologies for localized cutaneous leishmaniasis and potential for extensive network with capacities for clinical evaluation.

Olliaro P, Grogl M, Boni M, Carvalho EM, Chebli H, Cisse M, Diro E, Fernandes Cota G, Erber AC, Gadisa E, Handjani F, Khamesipour A, Llanos-Cuentas A, López Carvajal L, Grout L, Lmimouni BE, Mokni M, Nahzat MS, Ben Salah A, Ozbel Y, Pascale JM, Rizzo Molina N, Rode J, Romero G, Ruiz-Postigo JA, Gore Saravia N, Soto J, Uzun S, Mashayekhi V, Vélez ID, Vogt F, Zerpa O, Arana B.

PLoS Negl Trop Dis. 2018 Jan 12;12(1):e0006141. doi: 10.1371/journal.pntd.0006141. eCollection 2018 Jan.

30.

Cationic liposomes formulated with a novel whole Leishmania lysate (WLL) as a vaccine for leishmaniasis in murine model.

Jafari I, Heravi Shargh V, Shahryari M, Abbasi A, Jaafari MR, Khamesipour A, Badiee A.

Immunobiology. 2018 Jun - Jul;223(6-7):493-500. doi: 10.1016/j.imbio.2017.12.003. Epub 2017 Dec 28.

PMID:
29317110
31.

The role of LPD-nanoparticles containing recombinant major surface glycoprotein of Leishmania (rgp63) in protection against leishmaniasis in murine model.

Firouzmand H, Sahranavard M, Badiee A, Khamesipour A, Alavizadeh SH, Samiei A, Soroush D, Tavassoti Kheiri M, Mahboudi F, Jaafari MR.

Immunopharmacol Immunotoxicol. 2018 Feb;40(1):72-82. doi: 10.1080/08923973.2017.1407941. Epub 2017 Dec 6.

PMID:
29210292
32.

Liposomal adjuvant development for leishmaniasis vaccines.

Askarizadeh A, Jaafari MR, Khamesipour A, Badiee A.

Ther Adv Vaccines. 2017 Aug;5(4-5):85-101. doi: 10.1177/2051013617741578. Epub 2017 Nov 15. Review.

33.

Comparison of clinical efficacy and safety of thermotherapy versus cryotherapy in treatment of skin warts: A randomized controlled trial.

Izadi Firouzabadi L, Khamesipour A, Ghandi N, Hosseini H, Teymourpour A, Firooz A.

Dermatol Ther. 2018 Jan;31(1). doi: 10.1111/dth.12564. Epub 2017 Oct 30.

PMID:
29082602
34.

Assessing the Ovarian Accessory Glands to Determine the Parity of Phlebotomus papatasi, Vector of Zoonotic Cutaneous Leishmaniasis, under Laboratory Condition.

Fatemi M, Yaghoobi-Ershadi MR, Mohebali M, Saeidi Z, Veysi A, Khamesipour A, Akhavan AA.

J Arthropod Borne Dis. 2017 Mar 14;11(1):161-165. eCollection 2017 Mar.

35.

Iranian Native Plants on Treatment of Cutaneous Leishmaniosis: A Narrative Review.

Moghaddas E, Khamesipour A, Mohebali M, Fata A.

Iran J Parasitol. 2017 Jul-Sep;12(3):312-322. Review.

36.

PEGylation of cationic liposomes encapsulating soluble Leishmania antigens reduces the adjuvant efficacy of liposomes in murine model.

Naseri H, Eskandari F, Jaafari MR, Khamesipour A, Abbasi A, Badiee A.

Parasite Immunol. 2017 Nov;39(11). doi: 10.1111/pim.12492. Epub 2017 Oct 6.

37.

Genetic Diversity and Phylogenetic Analysis of the Iranian Leishmania Parasites Based on HSP70 Gene PCR-RFLP and Sequence Analysis.

Nemati S, Fazaeli A, Hajjaran H, Khamesipour A, Anbaran MF, Bozorgomid A, Zarei F.

Korean J Parasitol. 2017 Aug;55(4):367-374. doi: 10.3347/kjp.2017.55.4.367. Epub 2017 Aug 31.

38.

Identification of etiologic agents of cutaneous Leishmaniasis in palpebral position followed by effective therapy.

Saberi S, Arjmand R, Khamesipour A, Nilforoushzadeh MA, Sayareh S, Hejazi SH.

J Educ Health Promot. 2017 Jun 5;6:44. doi: 10.4103/jehp.jehp_118_14. eCollection 2017.

39.

Topical treatment with nanoliposomal Amphotericin B reduces early lesion growth but fails to induce cure in an experimental model of cutaneous leishmaniasis caused by Leishmania mexicana.

Varikuti S, Oghumu S, Saljoughian N, Pioso MS, Sedmak BE, Khamesipour A, Satoskar AR.

Acta Trop. 2017 Sep;173:102-108. doi: 10.1016/j.actatropica.2017.06.004. Epub 2017 Jun 9.

40.

Modulation of the Immune Response to DNA Vaccine Encoding Gene of 8-kDa Subunit of Echinococcus granulosus Antigen B Using Murine Interleukin-12 Plasmid in BALB/c Mice.

Azizi H, Kazemi B, Bandehpour M, Mohebali M, Khamesipour A, Aryaeipour M, Yaghoobi H, Rokni MB.

Iran J Parasitol. 2016 Oct-Dec;11(4):480-489.

41.

Aquaglyceroporin1 gene expression in antimony resistance and susceptible Leishmania major isolates.

Eslami G, Zarchi MV, Moradi A, Hejazi SH, Sohrevardi SM, Vakili M, Khamesipour A.

J Vector Borne Dis. 2016 Oct-Dec;53(4):370-374.

42.

The importance of the patient voice in vaccination and vaccine safety-are we listening?

Holt D, Bouder F, Elemuwa C, Gaedicke G, Khamesipour A, Kisler B, Kochhar S, Kutalek R, Maurer W, Obermeier P, Seeber L, Trusko B, Gould S, Rath B.

Clin Microbiol Infect. 2016 Dec 1;22 Suppl 5:S146-S153. doi: 10.1016/j.cmi.2016.09.027. Epub 2016 Dec 6.

43.

Anti Leishmania activity of Lucilia sericata and Calliphora vicina maggots in laboratory models.

Sanei-Dehkordi A, Khamesipour A, Akbarzadeh K, Akhavan AA, Mir Amin Mohammadi A, Mohammadi Y, Rassi Y, Oshaghi MA, Alebrahim Z, Eskandari SE, Rafinejad J.

Exp Parasitol. 2016 Nov;170:59-65. doi: 10.1016/j.exppara.2016.08.007. Epub 2016 Aug 24.

PMID:
27567983
44.
45.

Molecular Dynamics Simulation and Docking Studies of Selenocyanate Derivatives as Anti-Leishmanial Agents.

Iman M, Kaboutaraki HB, Jafari R, Hosseini SA, Moghimi A, Khamesipour A, Harchegani AB, Davood A.

Comb Chem High Throughput Screen. 2016;19(10):847-854. doi: 10.2174/1386207319666160907102235.

PMID:
27604957
46.

In vivo/In vitro immune responses to L. major isolates from patients with no clinical response to Glucantime.

Saberi S, Arjmand R, Soleimanifard S, Khamesipour A, Hosseini SM, Salehi M, Varshosaz J, Palizban AA, Hejazi SH.

Adv Biomed Res. 2016 Jul 29;5:126. doi: 10.4103/2277-9175.187000. eCollection 2016.

47.

Differential expression profiles of the salivary proteins SP15 and SP44 from Phlebotomus papatasi.

Hosseini-Vasoukolaei N, Idali F, Khamesipour A, Yaghoobi-Ershadi MR, Kamhawi S, Valenzuela JG, Edalatkhah H, Arandian MH, Mirhendi H, Emami S, Jafari R, Saeidi Z, Jeddi-Tehrani M, Akhavan AA.

Parasit Vectors. 2016 Jun 24;9(1):357. doi: 10.1186/s13071-016-1633-z.

48.

The role of ISCOMATRIX bilayer composition to induce a cell mediated immunity and protection against leishmaniasis in BALB/c mice.

Mehravaran A, Jaafari MR, Jalali SA, Khamesipour A, Ranjbar R, Hojatizade M, Badiee A.

Iran J Basic Med Sci. 2016 Feb;19(2):178-86.

49.

Coadminstration of L. major amastigote class I nuclease (rLmaCIN) with LPD nanoparticles delays the progression of skin lesion and the L. major dissemination to the spleen in BALB/c mice-based experimental setting.

Fakhraee F, Badiee A, Alavizadeh SH, Jalali SA, Chavoshian O, Khamesipour A, Mahboudi F, Jaafari MR.

Acta Trop. 2016 Jul;159:211-8. doi: 10.1016/j.actatropica.2016.04.004. Epub 2016 Apr 6.

PMID:
27060774
50.

Seasonal and Physiological Variations of Phlebotomus papatasi Salivary Gland Antigens in Central Iran.

Hosseini-Vasoukolaei N, Mahmoudi AR, Khamesipour A, Yaghoobi-Ershadi MR, Kamhawi S, Valenzuela JG, Arandian MH, Mirhendi H, Emami S, Saeidi Z, Idali F, Jafari R, Jeddi-Tehrani M, Akhavan AA.

J Arthropod Borne Dis. 2015 Jun 27;10(1):39-49. eCollection 2016 Mar.

Supplemental Content

Loading ...
Support Center